Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

312.67 +11.00 (+3.65%)
Streaming Delayed Price Updated: 12:32 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 399,567
Open 303.87
Bid (Size) 312.00 (40)
Ask (Size) 312.77 (160)
Prev. Close 301.67
Today's Range 303.00 - 317.17
52wk Range 273.11 - 495.55
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. ↗
Analysts have given Alnylam Pharmaceuticals an average price target of $436. 
Via The Motley Fool
News headline image
Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today ↗
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 10 years by 3.79% on an annualized basis producing an average annual ... 
Via Benzinga

Performance

YTD
-21.9%
-21.9%
1 Month
+5.8%
+5.8%
3 Month
-4.9%
-4.9%
6 Month
-21.4%
-21.4%
1 Year
-2.9%
-2.9%

More News

Read More
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Passes the "Little Book" Test with Explosive Growth and Upward Momentum ↗
Via Chartmill
ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY): A Decent Value Play with Strong Growth at a Discount to Peers ↗
Via Chartmill
News headline image
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shows Strong Growth and a Key Technical Setup ↗
Via Chartmill
Alnylam Pharmaceuticals (NASDAQ:ALNY): A GARP Candidate with Strong Growth and Reasonable Valuation ↗
Via Chartmill
News headline image
Alnylam Pharmaceuticals Unveils 2030 Targets, Betting on AMVUTTRA and Pipeline Readouts ↗
Via MarketBeat
News headline image
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
From Alnylam Pharmaceuticals, Inc. and Inceptive
Via Business Wire
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shows Strong Alignment with the Little Book That Makes You Rich Growth Strategy ↗
Via Chartmill
News headline image
Alnylam Issues 2025 Corporate Responsibility Report
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam’s First Billion-Dollar Quarter Smashes Q1 Estimates, ALNY Surges ↗
Via Chartmill
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): Strong Growth Fundamentals Align with a High-Probability Technical Setup ↗
Via Chartmill
News headline image
Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build ↗
Via MarketBeat
News headline image
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Presentations at Upcoming Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Emerges as a Top GARP Stock Pick ↗
Via Chartmill
News headline image
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam (ALNY) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation
Via Investor Brand Network
Topics Artificial Intelligence
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
Via Investor Brand Network
News headline image
Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
From BioMedWire
Via GlobeNewswire
News headline image
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
Via MarketMinute
Topics Intellectual Property Lawsuit

Frequently Asked Questions

Is Alnylam Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Alnylam Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Alnylam Pharmaceuticals, Inc. - Common Stock trade on?
Alnylam Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock is ALNY on the Nasdaq Stock Market
What is the current price of Alnylam Pharmaceuticals, Inc. - Common Stock?
The current price of Alnylam Pharmaceuticals, Inc. - Common Stock is 312.67
When was Alnylam Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Alnylam Pharmaceuticals, Inc. - Common Stock was at 07/02/26 12:32 PM ET
What is the market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock is 37.16B
How many shares of Alnylam Pharmaceuticals, Inc. - Common Stock are outstanding?
Alnylam Pharmaceuticals, Inc. - Common Stock has 37B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.